<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00470223</url>
  </required_header>
  <id_info>
    <org_study_id>Sarcome 09/0603</org_study_id>
    <secondary_id>UNICANCER-SARCOME-09-0603</secondary_id>
    <secondary_id>2006-003377-27</secondary_id>
    <nct_id>NCT00470223</nct_id>
  </id_info>
  <brief_title>Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma</brief_title>
  <acronym>OS2006</acronym>
  <official_title>OS2006 : Protocole de Traitement Des ostéosarcomes de l'Enfant, de l'Adolescent et de l'Adulte Comportant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SFCE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ligue contre le cancer, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor
      cells, either by killing the cells or by stopping them from dividing. Giving more than one
      drug (combination chemotherapy) may kill more tumor cells. Zoledronic acid may stop the
      growth of tumor cells in bone. Giving chemotherapy with or without zoledronic acid before
      surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be
      removed. Giving these treatments after surgery may kill any tumor cells that remain after
      surgery. It is not yet known whether giving combination chemotherapy together with zoledronic
      acid is more effective than combination chemotherapy alone in treating osteosarcoma.

      PURPOSE: This randomized phase III trial is studying combination chemotherapy and zoledronic
      acid to see how well they work compared with combination chemotherapy alone in treating
      patients with osteosarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the progression-free survival of patients with osteosarcoma treated with
           combination chemotherapy with or without zoledronic acid.

      Secondary

        -  Compare the overall survival of patients treated with these regimens.

        -  Compare the percentage of patients with a good histologic response.

        -  Compare the long and short term toxicity of these regimens in these patients.

        -  Compare the quality of life of patients treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age (&lt;
      18 years vs 18-25 years vs &gt; 25 years), risk group (nonmetastatic or resectable vs metastatic
      or unresectable), and treatment center. Patients receive either methotrexate-based
      chemotherapy or doxorubicin hydrochloride-based chemotherapy according to age.

        -  Methotrexate-based chemotherapy (patients ≤ 25 years of age): Patients are randomized to
           1 of 2 treatment arms.

             -  Arm I: Patients receive methotrexate IV in weeks 1-3, 7, 8, 12, and 13 and
                etoposide IV and ifosfamide IV in weeks 4 and 9.

             -  Arm II: Patients receive methotrexate, etoposide, and ifosfamide as in arm I.
                Patients also receive zoledronic acid IV in weeks 1, 5, 9, and 13.

      All patients undergo surgery in week 14. After surgery, patients are assigned to 1 of 2
      groups for further treatment, based on histological response.

        -  Good responders (&lt; 10% viable cells): Patients are randomized to 1 of 2 treatment arms.

             -  Arm I: Patients receive methotrexate IV in weeks 1-3, 7-9, 13-15, and 19-21 and
                etoposide IV in weeks 4 and 10. Patients also receive ifosfamide IV in weeks 4, 10,
                and 16.

             -  Arm II: Patients receive methotrexate, etoposide, and ifosfamide as in arm I.
                Patients also receive zoledronic acid IV in weeks 3, 7, 11, 15, 19, and 23.

        -  Bad responders (&gt; 10% viable cells): Patients are randomized to 1 of 2 treatment arms.

             -  Arm I: Patients receive methotrexate IV in weeks 1, 5, 9, 13, and 17 and
                doxorubicin hydrochloride IV and cisplatin IV in weeks 2, 6, 10, 14, and 18.

             -  Arm II: Patients receive methotrexate, doxorubicin hydrochloride, and cisplatin as
                in arm I. Patients also receive zoledronic acid IV as in arm II (good responders).

                  -  Doxorubicin hydrochloride-based chemotherapy (patients ≥ 18 years of age):
                     Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive doxorubicin hydrochloride IV and ifosfamide hydrochloride IV in
           weeks 1, 4, 7, 10, and 13 and cisplatin IV in weeks 1, 7, and 13.

        -  Arm II: Patients receive doxorubicin hydrochloride, ifosfamide, and cisplatin as in arm
           I. Patients also receive zoledronic acid IV in weeks 1, 5, 9, and 13.

      All patients undergo surgery in week 16. After surgery, patients are assigned to 1 of 2
      groups for further treatment, based on histological response.

        -  Good responders (&lt; 10% viable cells): Patients are randomized to 1 of 2 treatment arms.

             -  Arm I: Patients receive doxorubicin hydrochloride IV in weeks 1 and 7 and
                ifosfamide IV in weeks 1, 4, 7, and 10.

             -  Arm II: Patients receive doxorubicin hydrochloride and ifosfamide as in arm I.
                Patients also receive zoledronic acid IV in weeks 1, 5, 9, 13, 17, and 21.

        -  Bad responders (&gt; 10% viable cells):

             -  Arm I: Patients receive etoposide IV and ifosfamide IV in weeks 1, 4, 7, 10, and
                13.

             -  Arm II: Patients receive etoposide and ifosfamide as in arm I. Patients also
                receive zoledronic acid as in arm II (good responders).

      PROJECTED ACCRUAL: A total of 440 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    IDMC decision upon interim efficacy analysis
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of good responders</measure>
    <time_frame>at the time of the surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short term and long term toxicity</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">318</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Chemotherapy + zoledronicc acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Chemotherapy + zoledronicc acid</arm_group_label>
    <arm_group_label>chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Chemotherapy + zoledronicc acid</arm_group_label>
    <arm_group_label>chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <arm_group_label>Chemotherapy + zoledronicc acid</arm_group_label>
    <arm_group_label>chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <arm_group_label>Chemotherapy + zoledronicc acid</arm_group_label>
    <arm_group_label>chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>Chemotherapy + zoledronicc acid</arm_group_label>
    <arm_group_label>chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
    <arm_group_label>Chemotherapy + zoledronicc acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <arm_group_label>Chemotherapy + zoledronicc acid</arm_group_label>
    <arm_group_label>chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Histologically confirmed high-grade osteosarcoma

          -  Bilirubin ≤ 2 times upper limit of normal

          -  No medical condition that would preclude study treatment

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  Shortening fraction ≥ 28%

          -  LVEF ≥ 50%

          -  Glomerular filtration rate ≥ 70mL/min

          -  No recent dental problem, including infection, traumatization, or surgery

        Exclusion Criteria

          -  Low-grade osteosarcoma

          -  Small cell osteosarcoma

          -  Maxillary osteosarcoma

          -  Primary resected osteosarcoma

          -  Osteosarcoma with multiple metastases for which complete removal is not feasible even
             after shrinkage with chemotherapy

          -  Extra-osseous osteosarcoma

          -  Any prior osteonecrosis of the maxilla

          -  No prior chemotherapy or radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence Brugieres, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Angers</city>
        <zip>49036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR de Besancon - Hopital Saint-Jacques</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopital A. Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Clermont Ferrand, Hotel Dieu</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hopital Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot - Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital d'Enfants de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Rene Gauducheau</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de l'Archet CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>F-06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Bernard</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de la Loire</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaire de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Bastien de Clocheville</name>
      <address>
        <city>Tours</city>
        <zip>3700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours - Hopital Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2007</study_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>localized osteosarcoma</keyword>
  <keyword>metastatic osteosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared at an individual level, they will be part of the study database including all enrolled patients.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

